Bafna Pharmaceuticals Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: February 24, 2025, 11:25 pm

Market Cap	174 Cr.
Current Price	73.7
High / Low	113/67.8
Stock P/E	37.3
Book Value	35.0
Dividend Yield	0.00 %
ROCE	9.48 %
ROE	9.44 %
Face Value	10.0
PEG Ratio	0.24

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Bafna Pharmaceuticals Ltd

Competitors of Bafna Pharmaceuticals Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
MPS Pharmaa Ltd	7.42 Cr.	3.88	4.33/3.05		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	53.1 Cr.	71.5	94.9/30.8	18.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	39.3 Cr.	26.8	29.0/8.74	40.1	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	66.6 Cr.	88.4	155/81.2	10.8	55.4	0.00 %	14.4 %	15.5 %	10.0
Industry Average	16,989.19 Cr	1,062.76		42.33	185.19	0.37%	16.18%	16.43%	6.27

All Competitor Stocks of Bafna Pharmaceuticals Ltd

Quarterly Result

Metric	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Sales	17.48	21.84	21.26	28.44	20.46	14.98	16.93	21.96	34.22	42.24	41.95	40.68	28.44
Expenses	15.27	17.64	17.77	22.74	17.63	15.36	15.27	19.42	31.18	34.62	35.66	36.67	30.51
Operating Profit	2.21	4.20	3.49	5.70	2.83	-0.38	1.66	2.54	3.04	7.62	6.29	4.01	-2.07
OPM %	12.64%	19.23%	16.42%	20.04%	13.83%	-2.54%	9.81%	11.57%	8.88%	18.04%	14.99%	9.86%	-7.28%
Other Income	0.04	0.31	0.17	-1.79	0.49	1.04	1.30	0.64	1.93	0.26	1.87	0.16	0.98
Interest	0.33	0.38	0.11	0.11	0.41	0.21	0.31	0.45	0.58	0.70	0.60	0.44	0.58
Depreciation	1.02	1.50	1.46	1.42	1.21	1.40	1.29	1.12	1.40	1.53	1.21	1.24	1.27
Profit before tax	0.90	2.63	2.09	2.38	1.70	-0.95	1.36	1.61	2.99	5.65	6.35	2.49	-2.94
Tax %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.96%	0.00%	0.00%	0.00%
Net Profit	0.90	2.64	2.09	2.38	1.70	-0.95	1.36	1.61	3.00	5.37	6.35	2.48	-2.94
EPS in Rs	0.38	1.12	0.88	1.01	0.72	-0.40	0.57	0.68	1.27	2.27	2.68	1.05	-1.24

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

Metric	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Sales	124	167	177	100	85	65	46	44	42	71	85	115	153
Expenses	105	146	156	116	82	70	81	57	41	61	73	100	137
Operating Profit	18	21	21	-16	3	-5	-35	-13	1	10	12	16	16
OPM %	15%	13%	12%	-16%	3%	-8%	-77%	-30%	3%	14%	14%	14%	10%
Other Income	1	3	1	40	1	1	31	0	-23	1	-0	3	3
Interest	8	11	12	12	12	11	7	2	0	1	1	2	2
Depreciation	6	8	8	5	4	4	4	3	3	4	5	5	5
Profit before tax	5	5	2	6	-13	-19	-14	-18	-25	6	5	12	12
Tax %	61%	25%	40%	-0%	3%	4%	-15%	-8%	0%	0%	0%	2%
Net Profit	2	4	1	6	-12	-18	-16	-20	-25	6	5	11	11
EPS in Rs	1.13	2.08	0.72	3.28	-6.53	-9.90	-6.95	-8.34	-106.53	2.46	2.21	4.79	4.76
Dividend Payout %	0%	29%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2012-2013	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023
YoY Net Profit Growth (%)	100.00%	-75.00%	500.00%	-300.00%	-50.00%	11.11%	-25.00%	-25.00%	124.00%	-16.67%	120.00%
Change in YoY Net Profit Growth (%)	0.00%	-175.00%	575.00%	-800.00%	250.00%	61.11%	-36.11%	0.00%	149.00%	-140.67%	136.67%

Bafna Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:	-1%
5 Years:	28%
3 Years:	29%
TTM:	-3%

Compounded Profit Growth
10 Years:	18%
5 Years:	19%
3 Years:	8%
TTM:	-59%

Stock Price CAGR
10 Years:	11%
5 Years:	%
3 Years:	-16%
1 Year:	-17%

Return on Equity
10 Years:	-17%
5 Years:	10%
3 Years:	13%
Last Year:	9%

Last Updated: Unknown

Balance Sheet

Last Updated: February 12, 2025, 4:05 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	19	19	19	19	19	24	24	2	24	24	24	24	24
Reserves	49	50	53	41	26	17	-3	49	33	38	50	57	59
Borrowings	91	99	64	80	82	47	46	3	15	11	23	24	19
Other Liabilities	84	54	50	45	40	40	54	17	14	17	33	42	33
Total Liabilities	243	223	185	185	167	128	121	71	86	90	130	148	134
Fixed Assets	66	63	49	47	43	40	37	35	36	39	40	40	56
CWIP	-0	-0	-0	-0	-0	-0	-0	0	1	-0	2	12	2
Investments	1	1	18	18	18	1	1	-0	-0	-0	-0	-0	-0
Other Assets	175	158	118	120	106	86	82	36	50	51	88	95	77
Total Assets	243	223	185	185	167	128	121	71	86	90	130	148	134

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	35	1	9	-3	14	-7	-1	-34	-14	10	5	9
Cash from Investing Activity +	-6	-5	56	-1	-8	38	4	33	-5	-7	-7	-15
Cash from Financing Activity +	-11	-14	-66	4	-5	-31	-2	7	12	-5	10	-1
Net Cash Flow	18	-18	-0	0	-0	0	0	6	-7	-2	8	-6

Free Cash Flow

Month	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Free Cash Flow	18.00	-70.00	-78.00	-80.00	-77.00	-87.00	-82.00	-59.00	-2.00	-5.00	1.00	-7.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	187	192	303	291	302	195	208	52	49	63	130	109
Inventory Days	63	78	66	92	118	102	122	208	154	185	129	125
Days Payable	215	116	149	169	164	265	517	229	107	113	165	149
Cash Conversion Cycle	35	155	220	214	255	31	-188	31	96	135	94	84
Working Capital Days	150	204	250	320	207	79	-16	89	172	148	150	126
ROCE %	9%	9%	-13%	-0%	-6%	-36%	-21%	-3%	10%	11%	16%	9%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	90.42%	90.12%	90.00%	90.01%	89.99%	89.99%	88.73%	88.42%	88.29%	88.29%	88.29%	88.29%
Public	9.58%	9.88%	10.00%	9.98%	10.00%	10.00%	11.27%	11.57%	11.70%	11.71%	11.70%	11.70%
No. of Shareholders	7,326	7,223	7,275	7,199	7,120	6,992	7,354	7,367	7,539	7,391	7,295	7,214

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 20	Mar 19	Mar 18	Mar 17	Mar 16
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	-15.52	-11.48	-7.15	-10.43	-8.80
Diluted EPS (Rs.)	-15.52	-11.48	-7.15	-10.43	-8.80
Cash EPS (Rs.)	-89.52	-6.29	-5.47	-8.17	-5.51
Book Value[Excl.RevalReserv]/Share (Rs.)	-17.59	7.97	15.73	22.57	30.95
Book Value[Incl.RevalReserv]/Share (Rs.)	-17.59	7.97	15.73	22.57	30.95
Revenue From Operations / Share (Rs.)	179.54	18.33	19.94	34.82	45.73
PBDIT / Share (Rs.)	6.25	-5.36	-1.61	-2.50	1.34
PBIT / Share (Rs.)	-7.56	-6.83	-3.29	-4.76	-1.27
PBT / Share (Rs.)	-103.32	-7.30	-6.22	-10.91	-8.21
Net Profit / Share (Rs.)	-103.32	-7.76	-7.15	-10.43	-8.12
NP After MI And SOA / Share (Rs.)	-104.54	-7.98	-7.07	-10.23	-7.52
PBDIT Margin (%)	3.48	-29.26	-8.05	-7.18	2.92
PBIT Margin (%)	-4.20	-37.28	-16.47	-13.68	-2.76
PBT Margin (%)	-57.54	-39.86	-31.19	-31.34	-17.95
Net Profit Margin (%)	-57.54	-42.32	-35.84	-29.95	-17.74
NP After MI And SOA Margin (%)	-58.22	-43.52	-35.48	-29.38	-16.44
Return on Networth / Equity (%)	0.00	-99.01	-44.12	-44.73	-24.28
Return on Capital Employeed (%)	-3.29	-33.22	-9.90	-9.17	-2.41
Return On Assets (%)	-34.67	-15.79	-12.09	-10.70	-7.27
Long Term Debt / Equity (X)	-0.71	1.21	0.61	0.91	0.60
Total Debt / Equity (X)	-0.71	2.43	1.23	1.93	1.39
Asset Turnover Ratio (%)	0.44	0.33	0.30	0.36	0.44
Current Ratio (X)	2.11	0.68	0.81	0.94	1.29
Quick Ratio (X)	1.44	0.55	0.63	0.74	1.11
Inventory Turnover Ratio (X)	2.24	2.66	1.55	0.89	0.97
Interest Coverage Ratio (X)	15.48	-5.97	-0.54	-0.40	0.19
Interest Coverage Ratio (Post Tax) (X)	-18.72	-8.10	-1.44	-0.69	-0.16
Enterprise Value (Cr.)	-3.29	69.21	109.10	134.30	133.55
EV / Net Operating Revenue (X)	-0.07	1.60	2.31	2.07	1.57
EV / EBITDA (X)	-2.22	-5.45	-28.71	-28.76	53.52
MarketCap / Net Operating Revenue (X)	0.04	0.59	1.40	0.84	0.65
Price / BV (X)	-0.49	1.36	1.75	1.29	0.96
Price / Net Operating Revenue (X)	0.04	0.59	1.40	0.84	0.65
EarningsYield	-11.80	-0.72	-0.25	-0.34	-0.25

After reviewing the key financial ratios for Bafna Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 20, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 19) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
For Diluted EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
For Cash EPS (Rs.), as of Mar 20, the value is -89.52. This value is below the healthy minimum of 3. It has decreased from -6.29 (Mar 19) to -89.52, marking a decrease of 83.23.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
For Revenue From Operations / Share (Rs.), as of Mar 20, the value is 179.54. It has increased from 18.33 (Mar 19) to 179.54, marking an increase of 161.21.
For PBDIT / Share (Rs.), as of Mar 20, the value is 6.25. This value is within the healthy range. It has increased from -5.36 (Mar 19) to 6.25, marking an increase of 11.61.
For PBIT / Share (Rs.), as of Mar 20, the value is -7.56. This value is below the healthy minimum of 0. It has decreased from -6.83 (Mar 19) to -7.56, marking a decrease of 0.73.
For PBT / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 0. It has decreased from -7.30 (Mar 19) to -103.32, marking a decrease of 96.02.
For Net Profit / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 2. It has decreased from -7.76 (Mar 19) to -103.32, marking a decrease of 95.56.
For NP After MI And SOA / Share (Rs.), as of Mar 20, the value is -104.54. This value is below the healthy minimum of 2. It has decreased from -7.98 (Mar 19) to -104.54, marking a decrease of 96.56.
For PBDIT Margin (%), as of Mar 20, the value is 3.48. This value is below the healthy minimum of 10. It has increased from -29.26 (Mar 19) to 3.48, marking an increase of 32.74.
For PBIT Margin (%), as of Mar 20, the value is -4.20. This value is below the healthy minimum of 10. It has increased from -37.28 (Mar 19) to -4.20, marking an increase of 33.08.
For PBT Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 10. It has decreased from -39.86 (Mar 19) to -57.54, marking a decrease of 17.68.
For Net Profit Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 5. It has decreased from -42.32 (Mar 19) to -57.54, marking a decrease of 15.22.
For NP After MI And SOA Margin (%), as of Mar 20, the value is -58.22. This value is below the healthy minimum of 8. It has decreased from -43.52 (Mar 19) to -58.22, marking a decrease of 14.70.
For Return on Networth / Equity (%), as of Mar 20, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -99.01 (Mar 19) to 0.00, marking an increase of 99.01.
For Return on Capital Employeed (%), as of Mar 20, the value is -3.29. This value is below the healthy minimum of 10. It has increased from -33.22 (Mar 19) to -3.29, marking an increase of 29.93.
For Return On Assets (%), as of Mar 20, the value is -34.67. This value is below the healthy minimum of 5. It has decreased from -15.79 (Mar 19) to -34.67, marking a decrease of 18.88.
For Long Term Debt / Equity (X), as of Mar 20, the value is -0.71. This value is below the healthy minimum of 0.2. It has decreased from 1.21 (Mar 19) to -0.71, marking a decrease of 1.92.
For Total Debt / Equity (X), as of Mar 20, the value is -0.71. This value is within the healthy range. It has decreased from 2.43 (Mar 19) to -0.71, marking a decrease of 3.14.
For Asset Turnover Ratio (%), as of Mar 20, the value is 0.44. It has increased from 0.33 (Mar 19) to 0.44, marking an increase of 0.11.
For Current Ratio (X), as of Mar 20, the value is 2.11. This value is within the healthy range. It has increased from 0.68 (Mar 19) to 2.11, marking an increase of 1.43.
For Quick Ratio (X), as of Mar 20, the value is 1.44. This value is within the healthy range. It has increased from 0.55 (Mar 19) to 1.44, marking an increase of 0.89.
For Inventory Turnover Ratio (X), as of Mar 20, the value is 2.24. This value is below the healthy minimum of 4. It has decreased from 2.66 (Mar 19) to 2.24, marking a decrease of 0.42.
For Interest Coverage Ratio (X), as of Mar 20, the value is 15.48. This value is within the healthy range. It has increased from -5.97 (Mar 19) to 15.48, marking an increase of 21.45.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 20, the value is -18.72. This value is below the healthy minimum of 3. It has decreased from -8.10 (Mar 19) to -18.72, marking a decrease of 10.62.
For Enterprise Value (Cr.), as of Mar 20, the value is -3.29. It has decreased from 69.21 (Mar 19) to -3.29, marking a decrease of 72.50.
For EV / Net Operating Revenue (X), as of Mar 20, the value is -0.07. This value is below the healthy minimum of 1. It has decreased from 1.60 (Mar 19) to -0.07, marking a decrease of 1.67.
For EV / EBITDA (X), as of Mar 20, the value is -2.22. This value is below the healthy minimum of 5. It has increased from -5.45 (Mar 19) to -2.22, marking an increase of 3.23.
For MarketCap / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
For Price / BV (X), as of Mar 20, the value is -0.49. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 19) to -0.49, marking a decrease of 1.85.
For Price / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
For EarningsYield, as of Mar 20, the value is -11.80. This value is below the healthy minimum of 5. It has decreased from -0.72 (Mar 19) to -11.80, marking a decrease of 11.08.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation. If you have any questions or need more detailed insights, please feel free to reach out.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Bafna Pharmaceuticals Ltd as of February 25, 2025 is: ₹100.56

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 25, 2025, Bafna Pharmaceuticals Ltd is Undervalued by 36.45% compared to the current share price ₹73.70

Intrinsic Value of Bafna Pharmaceuticals Ltd as of February 25, 2025 is: 258.52

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 25, 2025, Bafna Pharmaceuticals Ltd is Undervalued by 250.77% compared to the current share price ₹73.70

Last 5 Year EPS CAGR: 157.08%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
	The stock has a low average ROCE of -1.25%, which may not be favorable. The stock has a high average Working Capital Days of 156.58, which may not be favorable. The stock has a high average Cash Conversion Cycle of 96.83, which may not be favorable. The company has higher borrowings (46.46) compared to reserves (39.92), which may suggest financial risk. The company has not shown consistent growth in sales (98.00) and profit (-2.77).

Strength

Weakness

The stock has a low average ROCE of -1.25%, which may not be favorable.
The stock has a high average Working Capital Days of 156.58, which may not be favorable.
The stock has a high average Cash Conversion Cycle of 96.83, which may not be favorable.
The company has higher borrowings (46.46) compared to reserves (39.92), which may suggest financial risk.
The company has not shown consistent growth in sales (98.00) and profit (-2.77).

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bafna Pharmaceuticals Ltd:
1. Net Profit Margin: -57.54%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: -3.29% (Industry Average ROCE: 16.05%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 0% (Industry Average ROE: 15.89%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): -18.72
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.44
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 37.3 (Industry average Stock P/E: 34.29)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: -0.71
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Bafna Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/03/1995 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L24294TN1995PLC030698 and registration number is 030698. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 152.47 Cr. and Equity Capital is Rs. 23.66 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Bafna Towers, New�No.�68,�Old�No. 299,�� Chennai (Madras) Tamil Nadu 600001	info@bafnapharma.com http://www.bafnapharma.com

Management
Name	Position Held
Mrs. S Hemalatha	Whole Time Director
Mrs. Akila C Raju	Non Exe.Non Ind.Director
Ms. R Chitra	Ind. Non-Executive Director
Mr. B Kamlesh Kumar	Ind. Non-Executive Director
Mr. P K Sundaresan	Ind. Non-Executive Director
Mr. Vinayak Dinesh Dendukuri	Whole Time Director
Mr. Upendar Mekala Reddy	Non Exe.Non Ind.Director
Mr. Krishna Yeachuri	Ind. Non-Executive Director

FAQ

What is the latest intrinsic value of Bafna Pharmaceuticals Ltd?

Let's break down Bafna Pharmaceuticals Ltd's intrinsic value simply:

We calculate intrinsic value using the PE Ratio Method - comparing the company's current price-to-earnings ratio with its historical average and industry peers. Think of it like checking if a stock is "on sale" compared to its typical pricing.

As of 25 February 2025:

Calculated Fair Value: ₹100.56
Current Market Price: ₹73.70
Variance: 36.45% higher

This suggests Bafna Pharmaceuticals Ltd is currently undervalued by 36.45%. For context:

Market Cap: 174 Cr.
52-Week Range: 113/67.8
Reserves (Sep 2024): ₹59 Cr
Liabilities: 134 Cr

Remember: The PE method gives a snapshot based on earnings multiples. While useful for quick comparisons, investors should also consider growth prospects, industry trends, and economic conditions. This calculation assumes historical PE ratios remain relevant - always verify with current market dynamics.

What is the Market Cap of Bafna Pharmaceuticals Ltd?

The Market Cap of Bafna Pharmaceuticals Ltd is 174 Cr..

What is the current Stock Price of Bafna Pharmaceuticals Ltd as on 25 February 2025?

The current stock price of Bafna Pharmaceuticals Ltd as on 25 February 2025 is ₹73.7.

What is the High / Low of Bafna Pharmaceuticals Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Bafna Pharmaceuticals Ltd stocks is 113/67.8.

What is the Stock P/E of Bafna Pharmaceuticals Ltd?

The Stock P/E of Bafna Pharmaceuticals Ltd is 37.3.

What is the Book Value of Bafna Pharmaceuticals Ltd?

The Book Value of Bafna Pharmaceuticals Ltd is 35.0.

What is the Dividend Yield of Bafna Pharmaceuticals Ltd?

The Dividend Yield of Bafna Pharmaceuticals Ltd is 0.00 %.

What is the ROCE of Bafna Pharmaceuticals Ltd?

The ROCE of Bafna Pharmaceuticals Ltd is 9.48 %.

What is the ROE of Bafna Pharmaceuticals Ltd?

The ROE of Bafna Pharmaceuticals Ltd is 9.44 %.

What is the Face Value of Bafna Pharmaceuticals Ltd?

The Face Value of Bafna Pharmaceuticals Ltd is 10.0.